Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: An update

Cytotherapy

Volumn 10, Issue 6, 2008, Pages 633-641

  Seggewiss, Ruth ^a   Price, D A ^b   Purbhoo, M A ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Dasatinib; Dendritic cell; Imatinib; Immunomodulation; T cell; Tyrosine kinase inhibitor

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COLONY STIMULATING FACTOR RECEPTOR; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DASATINIB; DORAMAPIMOD; IMATINIB; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NILOTINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; SGX 70430; SORAFENIB; STEM CELL FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE; SUNITINIB; T LYMPHOCYTE RECEPTOR; TANESPIMYCIN HYDROQUINONE; TYROSINE; UNCLASSIFIED DRUG; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; CANCER CELL; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG RESEARCH; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GROWTH INHIBITION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOMODULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 53749100337     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240802317639     Document Type: Article

References (87)

1. Druker, BJ, Talpaz, M. Resta, DJ et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 344, pp. 1031-1037.
2. Druker, BJ, Tamura, S. Buchdunger, E. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2, pp. 561-566.
3. Dewar, AL, Cambareri, AC Zannettino, AC et al. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood, 105, pp. 3127-3132.
4. O'Brien, SG, Guilhot, F. Larson, RA et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med, 348, pp. 994-1004.
5. Demetri, GD, von Mehren, M. Blanke, CD et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 347, pp. 472-480.
6. Bartolovic, K., Balabanov, S. Hartmann, U. et al. (2004) Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood, 103, pp. 523-529.
7. Mattiuzzi, GN, Cortes, JE Talpaz, M. et al. (2003) Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res, 9, pp. 976-980.
8. Bekkenk, MW, Vermeer, MH Meijer, CJ et al. (2003) EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate. Blood, 102, p. 4243.
9. Eklund, KK and Joensuu, H. (2003) Treatment of rheumatoid arthritis with imatinib mesylate: Clinical improvement in three refractory cases. Ann Med, 35, pp. 362-367.
10. Bhatia, R., Holtz, M. Niu, N. et al. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101, pp. 4701-4707.
11. Graham, SM, Jorgensen, HG Allan, E. et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, pp. 319-325.
12. Druker, B. J. (2006) Circumventing resistance to kinase-inhibitor therapy. N Engl J Med, 354, pp. 2594-2596.
13. Druker, BJ, Guilhot, F. O'Brien, SG et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 355, pp. 2408-2417.
14. Shah, NP, Tran, C. Lee, FY et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, pp. 399-401.
15. Talpaz, M., Shah, NP Kantarjian, H. et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354, pp. 2531-2541.
16. Copland, M., Hamilton, A. Elrick, LJ et al. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood, 107, pp. 4532-4539.
17. Rix, U., Hantschel, O. Durnberger, G. et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood, 110, pp. 4055-4063.
18. Wilhelm, S., Carter, C. Lynch, M. et al. (2006) Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov, 5, pp. 835-844.
19. Oka, H., Chatani, Y. Hoshino, R. et al. (1995) Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res, 55, pp. 4182-4187.
20. Huang, Y. and Wange, R. L. (2004) T cell receptor signaling: Beyond complex complexes. J Biol Chem, 279, pp. 28827-28830.
21. Palacios, EH and Weiss, A. (2004) Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene, 23, pp. 7990-8000.
22. Groves, T., Smiley, P. Cooke, MP et al. (1996) Fyn can partially substitute for Lck in T lymphocyte development. Immunity, 5, pp. 417-428.
23. Gorska, MM, Stafford, SJ Cen, O. et al. (2004) Unc119, a novel activator of Lck/Fyn, is essential for T cell activation. J Exp Med, 199, pp. 369-379.
24. Raab, M., da Silva, AJ Findell, PR et al. (1997) Regulation of Vav-SLP-76 binding by ZAP-70 and its relevance to TCR zeta/CD3 induction of interleukin-2. Immunity, 6, pp. 155-164.
25. Zhang, W., Sloan-Lancaster, J. Kitchen, J. et al. (1998) LAT: The ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell, 92, pp. 83-92.
26. Wardenburg, JB, Fu, C. Jackman, JK et al. (1996) Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function. J Biol Chem, 271, pp. 19641-19644.
27. Raab, M., Cai, YC Bunnell, SC et al. (1995) p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: Implications for T-cell costimulation. Proc Natl Acad Sci USA, 92, pp. 8891-8895.
28. Acuto, O. and Michel, F. (2003) CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nat Rev Immunol, 3, pp. 939-951.
29. Acuto, O., Mise-Omata, S. Mangino, G. et al. (2003) Molecular modifiers of T cell antigen receptor triggering threshold: The mechanism of CD28 costimulatory receptor. Immunol Rev, 192, pp. 21-31.
30. Chuang, E., Lee, KM Robbins, MD et al. (1999) Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases. J Immunol, 162, pp. 1270-1277.
31. Lee, KM, Chuang, E. Griffin, M. et al. (1998) Molecular basis of T cell inactivation by CTLA-4. Science, 282, pp. 2263-2266.
32. Zipfel, PA, Zhang, W. Quiroz, M. et al. (2004) Requirement for Abl kinases in T cell receptor signaling. Curr Biol, 14, pp. 1222-1231.
33. Druker, B. J. (2002) Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene, 21, pp. 8541-8546.
34. Roose, JP, Diehn, M. Tomlinson, MG et al. (2003) T cell receptor-independent basal signaling via Erk and Abl kinases suppresses RAG gene expression. PLoS Biol, 1, p. E53.
35. Schwartzberg, PL, Stall, AM Hardin, JD et al. (1991) Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell, 65, pp. 1165-1175.
36. Tybulewicz, VL, Crawford, CE Jackson, PK et al. (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell, 65, pp. 1153-1163.
37. Seggewiss, R., Lore, K. Greiner, E. et al. (2005) Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood, 105, pp. 2473-2479.
38. Dietz, AB, Souan, L. Knutson, GJ et al. (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood, 104, pp. 1094-1099.
39. Cwynarski, K., Laylor, R. Macchiarulo, E. et al. (2004) Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 18, pp. 1332-1339.
40. Fabian, MA, Biggs, WH 3rd Treiber, DK et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol, 23, pp. 329-336.
41. Weichsel, R., Dix, C. Wooldridge, L. et al. (2008) Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res, 14, pp. 2484-2491.
42. Schade, AE, Schieven, GL Townsend, R. et al. (2008) Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood, 111, pp. 1366-1377.
43. Blake, S., Hughes, TP Mayrhofer, G. et al. (2008) The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin Immunol, 127:3, pp. 330-339.
44. Chen, J., Schmitt, A. Chen, B. et al. (2008) Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signaling. J Cell Mol Med
45. Burchert, A., Wolfl, S. Schmidt, M. et al. (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood, 101, pp. 259-264.
46. Brauer, KM, Werth, D. von Schwarzenberg, K. et al. (2007) BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. Cancer Res, 67, pp. 5489-5497.
47. Wang, H., Cheng, F. Cuenca, A. et al. (2005) Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. Blood, 105, pp. 1135-1143.
48. Bocchia, M., Abruzzese, E. Forconi, F. et al. (2006) Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia, 20, pp. 142-143.
49. Seder, RA and Ahmed, R. (2003) Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat Immunol, 4, pp. 835-842.
50. Kantarjian, HM, O'Brien, S. Cortes, JE et al. (2002) Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood, 100, pp. 1590-1595.
51. Bornhauser, M., Kroger, N. Schwerdtfeger, R. et al. (2006) Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: A retrospective multicentre study. Eur J Haematol, 76, pp. 9-17.
52. Shimoni, A., Kroger, N. Zander, AR et al. (2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17, pp. 290-297.
53. Perz, JB, Khorashad, JS Marin, D. et al. (2006) Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica, 91, pp. 1145-1146.
54. Oehler, VG, Gooley, T. Snyder, DS et al. (2007) The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood, 109, pp. 1782-1789.
55. Weisser, M., Tischer, J. Schnittger, S. et al. (2006) A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica, 91, pp. 663-666.
56. Savani, BN, Montero, A. Kurlander, R. et al. (2005) Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation. Bone Marrow Transplant, 36, pp. 1009-1015.
57. Jabbour, E., Cortes, J. Kantarjian, H. et al. (2007) Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: No evidence for increased transplant-related toxicity. Cancer, 110, pp. 340-344.
58. Mohty, M., Blaise, D. Olive, D. et al. (2005) Imatinib: The narrow line between immune tolerance and activation. Trends Mol Med, 11, pp. 397-402.
59. Appel, S., Balabanov, S. Brummendorf, TH et al. (2005) Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells, 23, pp. 1082-1088.
60. Wolf, D., Tilg, H. Rumpold, H. et al. (2007) The kinase inhibitor imatinib: An immunosuppressive drug?. Curr Cancer Drug Targets, 7, pp. 251-258.
61. Appel, S. and Brossart, P. (2007) Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. Endocr Metab Immune Disord Drug Targets, 7, pp. 93-97.
62. Mumprecht, S., Matter, M. Pavelic, V. et al. (2006) Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood, 108, pp. 3406-3413.
63. Banchereau, J., Briere, F. Caux, C. et al. (2000) Immunobiology of dendritic cells. Annu Rev Immunol, 18, pp. 767-811.
64. Dittel, BN, Visintin, I. Merchant, RM et al. (1999) Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol, 163, pp. 32-39.
65. Ludewig, B., Odermatt, B. Landmann, S. et al. (1998) Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med, 188, pp. 1493-1501.
66. Banchereau, J., Pascual, V. and Palucka, A. K. (2004) Autoimmunity through cytokine-induced dendritic cell activation. Immunity, 20, pp. 539-550.
67. Chen, M., Wang, YH Wang, Y. et al. (2006) Dendritic cell apoptosis in the maintenance of immune tolerance. Science, 311, pp. 1160-1164.
68. Merad, M., Hoffmann, P. Ranheim, E. et al. (2004) Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med, 10, pp. 510-517.
69. Collin, MP, Munster, D. Clark, G. et al. (2005) In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation, 79, pp. 722-725.
70. Chan, GW, Gorgun, G. Miller, KB et al. (2003) Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biol Blood Marrow Transplant, 9, pp. 170-176.
71. Klangsinsirikul, P., Carter, GI Byrne, JL et al. (2002) Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood, 99, pp. 2586-2591.
72. Auffermann-Gretzinger, S., Eger, L. Schetelig, J. et al. (2007) Alemtuzumab depletes dendritic cells more effectively in blood than in skin: A pilot study in patients with chronic lymphocytic leukemia. Transplantation, 83, pp. 1268-1272.
73. Chu, CL and Lowell, C. A. (2005) The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol, 175, pp. 2880-2889.
74. Napolitani, G., Bortoletto, N. Racioppi, L. et al. (2003) Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. Eur J Immunol, 33, pp. 2832-2841.
75. Appel, S., Boehmler, AM Grunebach, F. et al. (2004) Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood, 103, pp. 538-544.
76. Appel, S., Rupf, A. Weck, MM et al. (2005) Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res, 11, pp. 1928-1940.
77. Taieb, J., Maruyama, K. Borg, C. et al. (2004) Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood, 103, pp. 1966-1967.
78. Dewar, AL, Domaschenz, RM Doherty, KV et al. (2003) Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia, 17, pp. 1713-1721.
79. Sato, N., Narita, M. Takahashi, M. et al. (2003) The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol, 21, pp. 67-75.
80. Kawakami, Y., Inagaki, N. Salek-Ardakani, S. et al. (2006) Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3. Proc Natl Acad Sci USA, 103, pp. 153-158.
81. Gagliardi, MC, Finocchi, A. Orlandi, P. et al. (2003) Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinaemia patients does not influence their differentiation, maturation and antigen-presenting cell function. Clin Exp Immunol, 133, pp. 115-122.
82. Hipp, MM, Hilf, N. Walter, S. et al. (2008) Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood, 111:12, pp. 5610-5620.
83. Taieb, J., Chaput, N. Menard, C. et al. (2006) A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med, 12, pp. 214-219.
84. Chan, CW, Crafton, E. Fan, HN et al. (2006) Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med, 12, pp. 207-213.
85. Deininger, M., Buchdunger, E. and Druker, B. J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105, pp. 2640-2653.
86. Boissel, N., Rousselot, P. Raffoux, E. et al. (2006) Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukoc Biol, 79, pp. 747-756.
87. Reeves, PM, Bommarius, B. Lebeis, S. et al. (2005) Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med, 11, pp. 731-739.